Eargo 7 vs Otofonix Groove

The Eargo 7 is a premium-priced OTC hearing aid at $2,550, earning a B grade with a SoundScore of 3.4/5 in our lab testing. This invisible-in-ear device ranks #38 of 65 OTC hearing aids tested, placing it in the top 57% of its category. In our testing, the Eargo 7 demonstrates solid speech clarity in quiet environments, scoring 3.1/5—0.33 points above the OTC category average. Own-voice comfort also performs above average at 2.9/5, which is +0.39 points versus typical OTC devices, though only mixed in absolute terms. However, speech understanding in noisy situations is a weakness, scoring just 1.0/5, which falls 0.44 points below the category average. The most notable limitation is music streaming, which scored 0.0/5 in our lab measurements—1.92 points below the OTC average. Feedback handling is solid at 3.8/5 in absolute terms, though this is 0.74 points below the category average of 4.54/5. The Eargo 7 may appeal to users prioritizing a completely invisible design who primarily need help with speech in quieter settings. However, given its premium price point, consumers should note that several lower-priced alternatives in our database achieved higher overall sound scores. Those who frequently stream music or struggle in noisy environments may want to explore other options.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.